{
  "id": "20",
  "title": "Protective macrophage function",
  "summary": "Loss of macrophage clearance capacity may allow damaging material to accumulate around sensory neurons.",
  "source_title": "Failure of macrophage dead-cell clearance",
  "page": "20_loss_of_protective_macrophages.html",
  "source_markdown": "sources/20_loss_of_protective_macrophages.md",
  "structured_data": "data/20_loss_of_protective_macrophages.json",
  "snapshot_date": "2026-09-14",
  "source_review_date": "2026-09-14",
  "scope_label": "Early type 2 diabetes",
  "scope_exception": false,
  "source_headline_markdown": "**Best judgment: about 8%; skeptical–favorable sensitivity: 0.2%–52%.** These are subjective probabilities of the complete human proposition, not treatment effects or statistical confidence limits. The main uncertainty is whether a measurable clearance deficit precedes human terminal loss. Reviewed 14 September 2026. [Probability method](probability_method.md) · [Collection index](README.md).",
  "probability_percent": {
    "skeptical": 0.1875,
    "base": 7.92,
    "favorable": 52.02
  },
  "probability_meaning": "Subjective belief in the complete causal proposition. Scenario endpoints are sensitivity products, not confidence limits.",
  "causal_proposition_markdown": "In adults with type 2 diabetes diagnosed within five years and no clinical DPN at entry, peripheral macrophages develop a persistent deficit in engulfing and digesting dead-cell material before their connected peptidergic C-fiber terminals are destroyed. Restoring this clearance function to a normal physiological capacity from entry would prevent at least **20% of five-year net terminal loss**, in a baseline-defined group accounting for at least **10% of incident DPN under reference care**.\n\nThis is a specific form of failed macrophage support: **defective clearance of already dead material**. It does not price every possible macrophage benefit. Reduced trophic secretion, failed recruitment despite normal function per cell, and excessive removal of living axons are different propositions. The broader observation that macrophages can protect metabolically stressed nerves is better supported than the exact clearance-deficit claim.\n\n**Reference and endpoint.** Reference care is contemporary diabetes care without the selective intervention below. Initiating glycemic, lipid, nutritional and mechanical exposures are comparable between intervention arms. Identify adult human peptidergic, unmyelinated sensory neurons at entry by combined molecular and anatomical classification. Track their actual distal skin arbors; loss of a peptide marker does not establish physical disappearance.\n\nFor each person, five-year net loss is terminal destruction minus terminal replacement, divided by baseline terminal amount. People receive equal weight, rather than weighting donors by the number of recovered cells or images. Define the relative preservation fraction:\n\n`B = (mean reference net loss − mean intervention net loss) / mean reference net loss.`\n\nThe reference mean must be positive. Pain, conduction, myelin thickness and staining intensity cannot substitute for this endpoint.\n\n**Finite groups.** Candidate groups are the whole eligible population, males, females, baseline BMI ≥30 kg/m², baseline HbA1c ≥7.5%, and a baseline clearance-deficit group defined below. No additional intersections are searched. Coverage is `C = P(group membership | incident DPN under reference care)`. Incident DPN means new bilateral length-dependent peripheral nerve signs accompanied by objective small-fiber loss or abnormal nerve conduction, with another cause excluded. Groups are defined without future treatment response.\n\n**Compartment and measurable deficit.** Map each target neuron's connected unit: its soma and satellite envelope, peripheral nerve course with associated Remak Schwann cells, and skin arbor. Include tissue macrophages within 100 µm of those structures, distinguishing them from satellite glia and other phagocytes by lineage and anatomy. A macrophage belongs to the same connected unit throughout the comparison, even when individual cells turn over.\n\nMeasure clearance capacity per macrophage using a common cargo challenge in the intact local biochemical environment. The cargo is irreversibly dead autologous dermal fibroblasts plus detached 1–5 µm membrane fragments from those cells, mixed 1:1 by starting protein mass. Supply five fibroblast-equivalents of cargo per macrophage over 24 hours. A cleared equivalent must be internalized by a macrophage and have at least 90% of its tagged protein and membrane-lipid mass converted to amino acids and lipid hydrolysis products within that period. Count labeled products to distinguish digestion from dye transfer, extracellular fragmentation or movement into another cell. The resulting rate is cleared equivalents per macrophage per day; use the median across macrophages in each connected unit.\n\nCompare with the distribution in age-, sex-, BMI- and site-matched adults without diabetes under the same challenge. A deficit is a rate **below the normal fifth percentile and below half the normal median**. R1 requires that deficit for **90 consecutive days in the first follow-up year**, before the first tracked terminal destruction in the arbor, in at least **10% of baseline target units**, averaged with equal person weight. The baseline-deficit group applies the same rate and unit thresholds during a 30-day entry observation. These are chosen operational boundaries, not discovered biological constants. The challenge measures capacity under a common load; it does not itself show that naturally occurring debris is injurious.\n\n**Selective intervention Q.** Beginning at entry, Q restores the recognition, engulfment and lysosomal digestion activities of the specified macrophages when their clearance capacity falls below the stated boundary, targeting the matched normal median capacity. It directly changes those activities only. It neither supplies a trophic factor independently nor directly repairs neurons, changes systemic glucose, increases macrophage number, or removes living tissue. Already dead cellular cargo is identified independently of whether removing it improves the nerve. The standard challenge is an ideal measurement capability, not a recurring injury imposed on the actual follow-up arbor.\n\nMacrophages still pay the energetic and material costs of clearance. Their viability, recruitment, signaling, metabolite release and effects on other cells can change downstream. Q does not hold these consequences fixed or erase unfavorable ones. It stops imposing restoration when capacity is above the deficit boundary. Unlimited capability is assumed for selective restoration and nonperturbing measurement; merely increasing MERTK or galectin-3 expression does not implement Q. If the stipulated capacity cannot be maintained without an additional independent intervention, that comparison has not tested Q.",
  "claims": [
    {
      "id": "R1",
      "source_id": "R1",
      "claim": "A candidate group meets the specified pre-loss, 90-day, 10%-of-units macrophage clearance-capacity deficit.",
      "claim_markdown": "A candidate group meets the specified pre-loss, 90-day, 10%-of-units macrophage clearance-capacity deficit.",
      "conditional_percent": {
        "skeptical": 15.0,
        "base": 40.0,
        "favorable": 80.0
      },
      "cumulative_base_percent": 40.0,
      "source_cumulative_display": "40.0%",
      "reason_markdown": "Failed clearance is biologically plausible, but the closest metabolic study measures recruitment and protection; human expression data do not establish function or early timing.",
      "question": "Is macrophage capacity to clear dead cells deficient for at least 90 days before terminal loss in at least 10% of nerve units?"
    },
    {
      "id": "R2",
      "source_id": "R2",
      "claim": "In at least one R1 group, Q reduces five-year net terminal loss by at least 5%: B≥0.05.",
      "claim_markdown": "In at least one R1 group, Q reduces five-year net terminal loss by at least 5%: B≥0.05.",
      "conditional_percent": {
        "skeptical": 20.0,
        "base": 55.0,
        "favorable": 85.0
      },
      "cumulative_base_percent": 22.0,
      "source_cumulative_display": "22.0%",
      "reason_markdown": "Protective mouse macrophage effects and MERTK perturbations support a causal contribution; clearance specificity, downstream costs and human C-fiber transfer remain unresolved.",
      "question": "Would restoring deficient macrophage dead-cell clearance avert at least 5% of five-year net terminal loss?"
    },
    {
      "id": "R3",
      "source_id": "R3",
      "claim": "At least one same group satisfying R2 reaches B≥0.20.",
      "claim_markdown": "At least one same group satisfying R2 reaches B≥0.20.",
      "conditional_percent": {
        "skeptical": 25.0,
        "base": 60.0,
        "favorable": 85.0
      },
      "cumulative_base_percent": 13.2,
      "source_cumulative_display": "13.2%",
      "reason_markdown": "Large removal effects make material protection possible, but removing a defense does not quantify the benefit from correcting a naturally occurring deficit.",
      "question": "Would restoring deficient macrophage dead-cell clearance avert at least 20% of five-year net terminal loss?"
    },
    {
      "id": "R4",
      "source_id": "R4",
      "claim": "At least one same group satisfying R3 accounts for C≥0.10 of reference-care incident DPN.",
      "claim_markdown": "At least one same group satisfying R3 accounts for C≥0.10 of reference-care incident DPN.",
      "conditional_percent": {
        "skeptical": 25.0,
        "base": 60.0,
        "favorable": 90.0
      },
      "cumulative_base_percent": 7.92,
      "source_cumulative_display": "7.9%",
      "reason_markdown": "A common metabolic process is plausible; prevalence of a qualifying human clearance deficit is unknown.",
      "question": "Does the benefiting subgroup account for at least 10% of incident DPN cases under reference care?"
    }
  ],
  "sections": [
    {
      "heading": "The causal claim and its scope",
      "markdown": "In adults with type 2 diabetes diagnosed within five years and no clinical DPN at entry, peripheral macrophages develop a persistent deficit in engulfing and digesting dead-cell material before their connected peptidergic C-fiber terminals are destroyed. Restoring this clearance function to a normal physiological capacity from entry would prevent at least **20% of five-year net terminal loss**, in a baseline-defined group accounting for at least **10% of incident DPN under reference care**.\n\nThis is a specific form of failed macrophage support: **defective clearance of already dead material**. It does not price every possible macrophage benefit. Reduced trophic secretion, failed recruitment despite normal function per cell, and excessive removal of living axons are different propositions. The broader observation that macrophages can protect metabolically stressed nerves is better supported than the exact clearance-deficit claim.\n\n**Reference and endpoint.** Reference care is contemporary diabetes care without the selective intervention below. Initiating glycemic, lipid, nutritional and mechanical exposures are comparable between intervention arms. Identify adult human peptidergic, unmyelinated sensory neurons at entry by combined molecular and anatomical classification. Track their actual distal skin arbors; loss of a peptide marker does not establish physical disappearance.\n\nFor each person, five-year net loss is terminal destruction minus terminal replacement, divided by baseline terminal amount. People receive equal weight, rather than weighting donors by the number of recovered cells or images. Define the relative preservation fraction:\n\n`B = (mean reference net loss − mean intervention net loss) / mean reference net loss.`\n\nThe reference mean must be positive. Pain, conduction, myelin thickness and staining intensity cannot substitute for this endpoint.\n\n**Finite groups.** Candidate groups are the whole eligible population, males, females, baseline BMI ≥30 kg/m², baseline HbA1c ≥7.5%, and a baseline clearance-deficit group defined below. No additional intersections are searched. Coverage is `C = P(group membership | incident DPN under reference care)`. Incident DPN means new bilateral length-dependent peripheral nerve signs accompanied by objective small-fiber loss or abnormal nerve conduction, with another cause excluded. Groups are defined without future treatment response.\n\n**Compartment and measurable deficit.** Map each target neuron's connected unit: its soma and satellite envelope, peripheral nerve course with associated Remak Schwann cells, and skin arbor. Include tissue macrophages within 100 µm of those structures, distinguishing them from satellite glia and other phagocytes by lineage and anatomy. A macrophage belongs to the same connected unit throughout the comparison, even when individual cells turn over.\n\nMeasure clearance capacity per macrophage using a common cargo challenge in the intact local biochemical environment. The cargo is irreversibly dead autologous dermal fibroblasts plus detached 1–5 µm membrane fragments from those cells, mixed 1:1 by starting protein mass. Supply five fibroblast-equivalents of cargo per macrophage over 24 hours. A cleared equivalent must be internalized by a macrophage and have at least 90% of its tagged protein and membrane-lipid mass converted to amino acids and lipid hydrolysis products within that period. Count labeled products to distinguish digestion from dye transfer, extracellular fragmentation or movement into another cell. The resulting rate is cleared equivalents per macrophage per day; use the median across macrophages in each connected unit.\n\nCompare with the distribution in age-, sex-, BMI- and site-matched adults without diabetes under the same challenge. A deficit is a rate **below the normal fifth percentile and below half the normal median**. R1 requires that deficit for **90 consecutive days in the first follow-up year**, before the first tracked terminal destruction in the arbor, in at least **10% of baseline target units**, averaged with equal person weight. The baseline-deficit group applies the same rate and unit thresholds during a 30-day entry observation. These are chosen operational boundaries, not discovered biological constants. The challenge measures capacity under a common load; it does not itself show that naturally occurring debris is injurious.\n\n**Selective intervention Q.** Beginning at entry, Q restores the recognition, engulfment and lysosomal digestion activities of the specified macrophages when their clearance capacity falls below the stated boundary, targeting the matched normal median capacity. It directly changes those activities only. It neither supplies a trophic factor independently nor directly repairs neurons, changes systemic glucose, increases macrophage number, or removes living tissue. Already dead cellular cargo is identified independently of whether removing it improves the nerve. The standard challenge is an ideal measurement capability, not a recurring injury imposed on the actual follow-up arbor.\n\nMacrophages still pay the energetic and material costs of clearance. Their viability, recruitment, signaling, metabolite release and effects on other cells can change downstream. Q does not hold these consequences fixed or erase unfavorable ones. It stops imposing restoration when capacity is above the deficit boundary. Unlimited capability is assumed for selective restoration and nonperturbing measurement; merely increasing MERTK or galectin-3 expression does not implement Q. If the stipulated capacity cannot be maintained without an additional independent intervention, that comparison has not tested Q."
    },
    {
      "heading": "Reasoning from the biology",
      "markdown": "Dead cells and detached membranes can remain outside phagocytes, enter macrophages, accumulate in incompletely digested compartments, or be fully processed. Each stage has a different meaning. A larger intracellular debris signal could indicate better uptake or worse digestion. A larger extracellular corpse burden could reflect faster production despite unchanged clearance. Macrophage abundance and a lysosomal gene signature do not resolve those alternatives.\n\nA clearance deficit could allow extracellular damage signals, oxidized material or persistent inflammatory stimuli to accumulate near a living neuron. Processing that material might reduce destruction, support replacement, or both. However, a macrophage can also become overloaded, release injurious products, or divert energy from another useful function. More processing is therefore not assumed to be beneficial.\n\nThe proposed sequence is:\n\n`reduced macrophage clearance capacity → altered local dead-material persistence and downstream responses → altered destruction and replacement → net terminal loss.`\n\nNo particular cytokine, receptor, death pathway or macrophage transcriptomic label is mandatory. The structural intervention comparison determines whether the measured deficit matters. Material from neighboring cells can precede target-terminal loss; debris from that terminal after its destruction cannot establish the required time order."
    },
    {
      "heading": "Evidence that moves the judgment",
      "markdown": "**The most relevant mouse study establishes protective activity, not its spontaneous failure.** Hakim and colleagues found macrophage recruitment in sciatic nerve during high-fat/high-fructose feeding, before detectable epidermal fiber loss. Peptidergic and general epidermal innervation were preserved at 12 weeks and reduced at 24 weeks. The measured recruitment and cell-state data principally concern the earlier period; a later collapse of clearance was not demonstrated. Diet was assigned by cage, and released plotted animal values lack cage identifiers, limiting how completely diet effects can be separated from cage effects. [Hakim et al., 2025](https://doi.org/10.1038/s41586-024-08535-1).\n\nDisrupting CCR2-dependent recruitment accelerated denervation. Cenicriviroc, a dual CCR2/CCR5 antagonist, was given at 20 mg/kg three times weekly during weeks 8–12. Its structural subset contained six vehicle and four treated mice after weight-loss exclusions and further histology subsampling. Reanalysis gives a difference of −12.24 epidermal fibers/mm (95% Welch interval −23.11 to −1.37), exact label-allocation p=0.0476. Across the natural heat, mechanical and IENFD outcome family, Holm-adjusted p=0.095. Global Ccr2 deletion gives related evidence within the same paper and model, not an independent laboratory replication. These perturbations remove recruitment; they do not identify a deficient clearance process in otherwise intact diabetic macrophages. [Hakim et al., 2025](https://doi.org/10.1038/s41586-024-08535-1).\n\nGlobal galectin-3 deletion provides another structural comparison: **nine wild-type versus ten knockout mice**, both on the diet, averaged 58.71 versus 49.24 PGP9.5-positive epidermal fibers/mm. The difference is −9.47 (95% Welch interval −16.13 to −2.80), exact allocation p=0.00877. That is 16.1% lower density than wild type, **not** 16.1% of diabetic loss prevented. The intervention endpoint is mixed epidermal fibers, and the deletion is not macrophage-specific. Galectin-3 affects multiple intracellular and extracellular processes. The authors propose clearance of harmful material and other protective functions, but do not measure mediation through the clearance function defined here. The source shows plotted experiments representative of repeated work; those statements do not supply additional independently reanalyzable animals. [Hakim et al., 2025](https://doi.org/10.1038/s41586-024-08535-1).\n\n**Human data establish cells and states, with no direct capacity measurement.** A 2026 human DRG preprint identifies satellite microglia-like cells as a resident macrophage population. Its master table has 92 samples from 87 independent donors. Reanalysis of 11 donors with diabetes without recorded DPN versus 29 controls does not identify an early loss of the homeostatic population. But the unadjusted homeostatic-cell log-odds contrast has a 95% interval from −1.15 to 1.61: on the odds scale, approximately **0.32–4.98**. This is far too wide to establish equivalence. Mean ages were 54.2 versus 38.9 years. Recovered-cell proportions are not absolute tissue density, and neither quantity is a clearance assay. [Mazhar et al., 2026 preprint](https://pmc.ncbi.nlm.nih.gov/articles/PMC13192958/).\n\nIn established DPN, both homeostatic and disease-associated macrophage populations increase; that does not establish conversion from useful cells to failed cells. The spatial component uses **three control and three DPN donors**, not its 16 tissue samples or thousands of spots as independent people. Suggested nodule stages are reconstructed from cross-sections around dying or absent neuronal somata. They cannot determine whether a clearance defect preceded distal-terminal injury. Functional signaling and phagocytosis remain predictions from localization and expression. [Mazhar et al., 2026 preprint](https://pmc.ncbi.nlm.nih.gov/articles/PMC13192958/).\n\n**Other perturbations support plausibility while leaving the target gap open.** In traumatic partial nerve injury, preventing MERTK receptor cleavage reduced pain behavior and myelinated nerve damage; myeloid Mertk deletion worsened outcomes. Transfer of cleavage-resistant macrophages relieved allodynia. The ultrastructural comparison used **three animals per group**, with eight images per animal. The corpse-clearance measure was a ratio of free to macrophage-associated TUNEL-positive material, generally four to six animals per contrast. That supports the proposed route but does not directly measure completed digestion or distinguish every change in corpse production. Global cleavage resistance can also affect Schwann-cell MERTK. Remak axons per bundle did not show a genotype difference. This is evidence about established traumatic injury and predominantly myelinated structure, rather than incident diabetic C-fiber loss. [Pandey et al., 2026](https://pmc.ncbi.nlm.nih.gov/articles/PMC12773720/).\n\nA high-fat/STZ rat study found more nerve abnormalities after systemic MERTK inhibitor MRX2843. It allocated 14 rats to each group but reported final groups of 10–14. MERTK protein was increased in diabetes rather than showing a spontaneous loss. The study's Schwann-cell knockdown experiments and systemic intervention do not isolate macrophages; glycated hemoglobin and lipids also worsened despite no reported spot-glucose change. Its qualitative sciatic pathology and conduction outcome do not establish terminal preservation. [Su et al., 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC11251753/).\n\nA 2026 STZ pain study reports that galectin-3 knockdown reduces myelin phagocytosis and allodynia, opposite to a simple “more galectin-3 is better” rule. The accessible primary abstract does not provide a peptidergic terminal outcome or enough animal-level details for reanalysis. Intrathecal manipulation, myelin handling and pain differ from peripheral dead-cell clearance and net C-fiber structure. This result limits a universal marker-based interpretation; it is not a direct negative test of Q. [YTHDF1/galectin-3 study, 2026](https://doi.org/10.1016/j.intimp.2026.117097).\n\nThe quantitative support is in [the macrophage finding](../../../findings/damage_calibration_macrophage_quantitative.md). No available result directly estimates the early human clearance deficit or the fraction of five-year target-terminal loss it causes."
    },
    {
      "heading": "Probabilities of the logical claims",
      "markdown": "Later probabilities assume every earlier claim holds for the **same candidate group**. Where several groups remain, a later claim asks whether at least one still qualifies. Different groups or disconnected cell populations cannot supply different links.\n\n| # | Claim | Skeptical / best / favorable | Best cumulative | Basis |\n|---|---|---:|---:|---|\n| R1 | A candidate group meets the specified pre-loss, 90-day, 10%-of-units macrophage clearance-capacity deficit. | 15 / **40** / 80% | 40.0% | Failed clearance is biologically plausible, but the closest metabolic study measures recruitment and protection; human expression data do not establish function or early timing. |\n| R2 | In at least one R1 group, Q reduces five-year net terminal loss by at least 5%: B≥0.05. | 20 / **55** / 85% | 22.0% | Protective mouse macrophage effects and MERTK perturbations support a causal contribution; clearance specificity, downstream costs and human C-fiber transfer remain unresolved. |\n| R3 | At least one same group satisfying R2 reaches B≥0.20. | 25 / **60** / 85% | 13.2% | Large removal effects make material protection possible, but removing a defense does not quantify the benefit from correcting a naturally occurring deficit. |\n| R4 | At least one same group satisfying R3 accounts for C≥0.10 of reference-care incident DPN. | 25 / **60** / 90% | **7.9%** | A common metabolic process is plausible; prevalence of a qualifying human clearance deficit is unknown. |\n\nR1 defines a functional state without calling it harmful. R2 tests its causal contribution, R3 its additional magnitude, and R4 its population coverage. A separate requirement that native macrophages already confer protection is unnecessary: the hypothesis concerns the effect of correcting a measured deficit, which R2 tests directly."
    },
    {
      "heading": "Ideal experiments that would resolve each claim",
      "markdown": "The shared ideal program observes a representative early-T2 cohort and matched nondiabetic reference participants, maps connected cells and arbors, measures clearance without altering their subsequent course, and follows physical terminal destruction and replacement for five years. These are truth conditions under unlimited capability, not proposed laboratory work.\n\n**R1 — capacity before loss; no preceding claim assumed.** Resolve macrophage identity and perform the specified standardized cargo measurements, including both internalization and chemical digestion. Track the normal distribution, per-unit median capacity and first terminal destruction. Apply the finite baseline groups. **YES:** one group meets the rate, 90-day first-year, pre-destruction and 10%-of-units boundaries together. **NO:** complete observation shows every group fails at least one boundary. More corpse material, fewer transcripts or a late deficit alone leave the exact early-capacity claim **unresolved**. A normal capacity despite abundant debris can make R1 false.\n\n**R2 — structural causation conditional on R1.** Randomly allocate people within each R1-compatible group to reference care or Q from entry. Verify restoration of the defined macrophage capacity, absence of independent neuronal or metabolic treatment, and the actual handling of native dead material. Measure five-year destruction and replacement while allowing the energetic, immune and trophic consequences of clearance. **YES:** one compatible group has a positive reference-loss denominator and B≥0.05. **NO:** every faithfully implemented comparison has B<0.05, including net harm. Failure to restore capacity, missing physical structure, or analgesia alone leaves the comparison **unresolved**. Successful clearance without structural benefit makes this claim false even if R1 is true.\n\n**R3 — magnitude conditional on R1–R2.** Use the same groups, intervention and five-year endpoint. **YES:** at least one R2 group has B≥0.20. **NO:** every R2 group has 0.05≤B<0.20. Early preservation that disappears by year five does not meet the boundary. A finite estimate spanning 0.20 is **unresolved**, rather than being decided by significance against zero.\n\n**R4 — coverage conditional on R1–R3.** Determine baseline membership and incident DPN in the representative reference-care population. **YES:** at least one R3 group has C≥0.10. **NO:** all such groups have C<0.10. Do not combine overlapping groups after seeing outcomes or define a group as responders. Incomplete incident ascertainment leaves coverage **unresolved**.\n\nExact population values determine truth. Finite observations can remain unresolved when their uncertainty crosses a boundary."
    },
    {
      "heading": "Uncertainty and sensitivity",
      "markdown": "The best conditionals **[40,55,60,60]%** give **7.92%**, reported as about 8%. Skeptical **[15,20,25,25]%** and favorable **[80,85,85,90]%** scenarios give **0.1875%** and **52.02%**. These are coordinated biological interpretations, without assigned scenario weights or a justified variance. They are not independently fitted parameters or a clinical prediction model.\n\nIf observed macrophage changes mainly follow injury and clearance does not control terminal survival, **[25,35,40,40]%** gives **1.4%**. If a common early human deficit is established and the perturbation evidence transfers well, **[65,75,75,80]%** gives **29.25%**. The wide span reflects uncertainty about the exact function and its human timing, not just sampling error in one mouse experiment.\n\nChanging R1 alone from 40% to 75% after convincing pre-loss human functional evidence gives **14.85%**. Reducing it to 15% after adequate longitudinal evidence of maintained capacity gives **2.97%**. A null expression contrast cannot justify that latter update. Merging R1 and R2 must give their joint probability of **22%**, preserving the headline; dividing uptake and digestion into explanatory steps must not create automatic extra penalties.\n\nAllowing a milder deficit, a shorter duration, 10% rather than 20% preservation, or 5% rather than 10% case coverage weakens the proposition and cannot lower its probability when everything else stays fixed. This evidence does not support numerical repricing of each alternative. Changing the cargo panel or adding trophic functions changes the proposition itself, rather than merely its confidence interval."
    },
    {
      "heading": "Overlap and boundary",
      "markdown": "Clearance can influence [TNF/TLR4 signaling](19_tnf_tlr4_inflammation.md), [skin repair](32_skin_repair_environment.md), [oxidative injury](39_oxidative_nitrosative_injury.md), and responses to lipid or carbonyl stress. Those descriptions can concern the same prevented terminal loss and cannot be added as independent effects.\n\nThe present price concerns a persistent, measurable clearance deficit. Protective recruitment in obesity, pain resolution after traumatic injury, or improved wound healing can be real while this exact early-human prevention proposition is false."
    }
  ],
  "source_claim_table_markdown": "| # | Claim | Skeptical / best / favorable | Best cumulative | Basis |\n|---|---|---:|---:|---|\n| R1 | A candidate group meets the specified pre-loss, 90-day, 10%-of-units macrophage clearance-capacity deficit. | 15 / **40** / 80% | 40.0% | Failed clearance is biologically plausible, but the closest metabolic study measures recruitment and protection; human expression data do not establish function or early timing. |\n| R2 | In at least one R1 group, Q reduces five-year net terminal loss by at least 5%: B≥0.05. | 20 / **55** / 85% | 22.0% | Protective mouse macrophage effects and MERTK perturbations support a causal contribution; clearance specificity, downstream costs and human C-fiber transfer remain unresolved. |\n| R3 | At least one same group satisfying R2 reaches B≥0.20. | 25 / **60** / 85% | 13.2% | Large removal effects make material protection possible, but removing a defense does not quantify the benefit from correcting a naturally occurring deficit. |\n| R4 | At least one same group satisfying R3 accounts for C≥0.10 of reference-care incident DPN. | 25 / **60** / 90% | **7.9%** | A common metabolic process is plausible; prevalence of a qualifying human clearance deficit is unknown. |"
}